BACKGROUND: Coronavirus disease 2019 (COVID-19) represents an important infectious complication associated with high mortality rates in patients with hematologic diseases. There have not been published any epidemiologic studies from Czech Republic so far. PATIENTS AND METHODS: This study is the first analysis of patients with hematologic malignancies and bone marrow failure syndromes treated at single hematology center in the Czech Republic between March 1 and December 31, 2020, in whom COVID-19 infection was confirmed. RESULTS: The sample comprised 96 patients aged 26 to 84 years (median, 66.0 years). At the time of their COVID-19 diagnosis, 75 patients (78.1%) were treated for hematologic diseases. Twenty-seven patients (28.1%) in the sample had complete remission (CR) of their hematologic disease. They were nonsignificantly more likely to have asymptomatic to moderate COVID-19 infection than those who failed to achieve CR (74.1% vs. 56.5%; P = .06). A more severe course of the infection was significantly correlated with older age (P = .047). Lung involvement was also statistically significantly associated with older age (P = .045). Over the study period, a total of 15 patients died. Age greater than 60 years was significantly associated with deaths from COVID-19 (P = .036), with failure to achieve CR having a statistically nonsignificant impact on mortality (P = .22). CONCLUSION: These results confirm the prognostic significance of age for achieving treatment response of hematologic disease as well as the severity and mortality of COVID-19 in hematology patients.

Department of Anesthesiology and Intensive Care Medicine Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc

Department of Mathematical Analysis and Application of Mathematics Faculty of Science Palacký University Olomouc Olomouc Czech Republic

Department of Microbiology Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc

Faculty of Medicine and Dentistry Palacký University Olomouc

Zobrazit více v PubMed

Gorbalenya A.E., Baker S.C., Baric R.S., et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544. PubMed PMC

Shilpa P., Rausch C.R., Jain N., et al. Treating leukemia in the time of COVID-19. Acta Haematol. 2021;144:132–145. PubMed PMC

Williams M., Mi E., Le Calvez K., et al. Estimating the risk of death from COVID-19 in adult cancer patients. Clin Oncol (R Coll Radiol) 2021;33:e172–e179. PubMed PMC

Vijenthira A., Gong I.Y., Fox T.A., et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. PubMed PMC

Borah P., Mirgh S., Sharma K.S., et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2020;87 PubMed PMC

Infante M.S., Marín I.G., Muñoz-Novas C., et al. COVID-19 in patients with hematological malignancies: a retrospective case series. Int J Lab Hematol. 2020;42:e256–e259. PubMed PMC

García-Suárez J., Cruz J., Cedillo Á., et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133. PubMed PMC

Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. Uptodate.com. Available at: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-management-in-hospitalized-adults; 2021. Accessed January 21, 2021.

Clinical management of COVID-19. Who.int. https://www.who.int/publications/i/item/clinical-management-of-covid-19; 2021. Accessed January 21, 2021.

Doubek M, Mayer J, editors. Léčebné Postupy v Hematologii [in Czech] Tribun EU; Brno: 2020.

Epidemiology of covid-19 infection in patients with hematological malignancies: A European Haematology Association survey. Seifem.org. https://seifem.org/wp-content/uploads/2020/11/1-EPICOVIDEHA-synopsis-LIVIO-PAGANO.pdf; 2021. Accessed February 12, 2021.

iCMLf - COVID-19 case collection and case discussion. CML-foundation.org. https://www.cml-foundation.org/covid-19-hub/1462-the-international-cml-foundation-and-covid-19-covid-19-case-collection-2.html; 2021. Accessed February 12, 2021.

Girmenia C., Gentile G., Micozzi A., et al. COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome. Acta Haematol. 2020;143:574–582. PubMed

Foà R., Bonifacio M., Chiaretti S., et al. Ph+ acute lymphoblastic leukaemia in Italy during the Covid-19 pandemic: a Campus ALL study. Br J Haematol. 2020;190:e3–e5. PubMed PMC

Breccia M., Abruzzese E., Bocchia M., et al. Campus CML working group. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia. 2020;34:2260–2261. PubMed PMC

Li W., Wang D., Guo J., et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34:1799–1804. PubMed PMC

Yigenoglu T.N., Ata N., Altuntas F., et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93:1099–1104. PubMed PMC

Treon S.P., Castillo J.J., Skarbnik A.P., et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135:1912–1915. PubMed PMC

Derosa L., Melenotte C., Griscelli F., et al. The immuno-oncological challenge of COVID-19. Nature Cancer. 2020;1:946–964. PubMed

Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. PubMed PMC

Deng Y., Liu W., Liu K., et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020;133:1261–1267. PubMed PMC

Sahu B.R., Kampa R.K., Padhi A., et al. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta. 2020;509:91–94. PubMed PMC

Elkrief A., Desilets A., Papneja N., et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181–187. PubMed PMC

Shah V., Ko Ko T., Zuckerman M., et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190:e268–e288. PubMed PMC

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies-The First Single-Centre Experience from the Czech Republic